SANDOZ RIVASTIGMINE PATCH 10

国: カナダ

言語: 英語

ソース: Health Canada

有効成分:

RIVASTIGMINE

から入手可能:

SANDOZ CANADA INCORPORATED

ATCコード:

N06DA03

INN（国際名）:

RIVASTIGMINE

投薬量:

9.5MG

医薬品形態:

PATCH

構図:

RIVASTIGMINE 9.5MG

投与経路:

TRANSDERMAL

パッケージ内のユニット:

30

処方タイプ:

Prescription

治療領域:

PARASYMPATHOMEMETIC (CHOLINERGIC) AGENTS

製品概要:

Active ingredient group (AIG) number: 0140521008; AHFS:

認証ステータス:

APPROVED

承認日:

2014-07-11

製品の特徴

_ _
SANDOZ RIVASTIGMINE PATCH (Rivastigmine Hydrogen Tartrate)
_ _
_Page 1 of 58_
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
Pr
SANDOZ RIVASTIGMINE PATCH 5
Pr
SANDOZ RIVASTIGMINE PATCH 10
Rivastigmine Transdermal Patch
Patch, 4.6 mg/24 h and 9.5 mg/24h, Transdermal
Cholinesterase Inhibitor
Submission Control Number:
280181
Sandoz Canada
Inc. Date of InitialAuthorization:
110, rue de Lauzon JUL 11, 2014
Boucherville, QC
Canada
J4B 1E6 Date of Revision:
NOV 27, 2023
_ _
SANDOZ RIVASTIGMINE PATCH (Rivastigmine Hydrogen Tartrate)
_ _
_Page 2 of 58_
RECENT MAJOR LABEL CHANGES
2 CONTRAINDICATIONS
11/2023
7 WARNINGS AND PRECAUTIONS, Cardiovascular
11/2023
TABLE OF CONTENTS
RECENT MAJOR LABEL CHANGES
............................................................................................
2
TABLE OF CONTENTS
..............................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
......................................................................
4
1
INDICATIONS
..............................................................................................................
4
1.1
Pediatrics
...................................................................................................................
4
1.2
Geriatrics
...................................................................................................................
4
2
CONTRAINDICATIONS
.................................................................................................
4
3
SERIOUS WARNINGS AND PRECAUTIONS BOX
............................................................. 4
4
DOSAGE AND ADMINISTRATION
.................................................................................
5
4.1
Dosing Considerations
...............................................................................................
5
4.2
Recommended Dose and Dosage Adjustment
......................................................... 5
4.4
Administration
.................